Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.
Massachusetts-based Boston Scientific generates most of its revenue from sales of its heart devices, such as pacemakers and stents. It also makes equipment to diagnose and treat a range of ...
Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...
Boston Scientific disclaims any intention or obligation ... which received FDA approval in the quarter and our EMPOWUR leadless pacemaker, which we now have submitted to the FDA.